A Clinical Therapeutic Trial of Cyclosporine in Myasthenia Gravis

Annals of the New York Academy of Sciences

Volumn 681, Issue 1, 1993, Pages 539-551

  TINDALL, RICHARD S A ^b   PHILLIPS, J THEODORE ^a   ROLLINS, JULIA A ^a   WELLS, LIESELOTTE ^a   HALL, KAREN ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PYRIDOSTIGMINE;

ADULT; AGED; ANTIBODY TITER; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; MALE; MENTAL DISEASE; MYASTHENIA GRAVIS; NEPHROTOXICITY; PRIORITY JOURNAL; STEROID THERAPY; STRENGTH; T LYMPHOCYTE; THYMECTOMY;

ADULT; AGED; AUTOANTIBODIES; CYCLOSPORINE; DOUBLE-BLIND METHOD; FEMALE; HUMAN; MALE; MIDDLE AGE; MYASTHENIA GRAVIS; PREDNISONE; RECEPTORS, NICOTINIC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027319951     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1993.tb22937.x     Document Type: Article

References (20)

1. Chemistry of the natural cyclosporin metabolites
2. Experimental autoimmunity
3. Cyclosporine: the agent and its actions
4. Effects of cyclosporine on human T cell activation
5. Nuclear association of a T‐cell transcription factor blocked by FK‐506 and cyclosporine A
6. The immunosuppressive macrolides FK‐506 and rapamycin
7. Immunology of acetylcholine receptors in relation to myasthenia gravis
8. Treatment of experimental myasthenia gravis with cyclosporine A
9. Preliminary results of a double‐blind, randomized placebo‐controlled trial of cyclosporine in myasthenia gravis
10. Cyclosporine in the treatment of myasthenia gravis
11. Myasthenia gravis and myasthenic syndromes
12. Cellular and molecular mechanisms of cyclosporine nephrotoxicity
13. Cyclosporine A vs. azathioprine in the treatment of myasthenia gravis: final results of a randomized, controlled double‐blind clinical trial
14. The mechanism of T‐cell activation in myasthenia gravis
15. T‐cell receptor genes in autoimmunity
16. Differences in fine specificity of anti‐acetylcholine receptor antibodies between subgroups of spontaneous myasthenia gravis of recent onset, and of penicillamine induced myasthenia
17. Acetylcholine receptor presentation by B cells using heterobifunctional antibody conjugates
18. An in vitro model for disease‐specific immunotherapy in myasthenia gravis using soluble MHC class II bound to AChR‐derived peptide